Verve Therapeutics Inc at Bank of America Healthcare Conference Transcript
The afternoon session of Day 2 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, it's my pleasure to introduce Sek Kathiresan, CEO of Verve Therapeutics. Take it away, Sek.
Thank you very much, Greg. Really a pleasure to be here. Happy to share the Verve story with you all. Okay, the problem we're trying to solve is atherosclerotic cardiovascular disease. This is really a problem of LDL cholesterol clogging the heart arteries. It's a leading cause of death worldwide, hundreds of millions of patients worldwide. And we're initially focused on a genetic subset of the disease called familial hypercholesterolemia, specifically heterozygous FH and then homozygous FH. And there are about 31 million people in the world with this genetic subset of atherosclerotic cardiovascular disease.
Now the solution to atherosclerotic cardiovascular disease has
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
